Multiple Myeloma: all 3,712 studies
Page 4 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- Pre-malignant States to Hematologic Malignancies in FirefightersRecruitingNCT06870760
- The Norwegian Immunotherapy in Multiple Myeloma StudyRecruitingNCT06855121
- Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.RecruitingNCT06846905
- ELISA in Relapsed/Refractory MMRecruitingNCT06832865Phase 2
- Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early RelapseRecruitingNCT06827860Phase 2
- Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell TherapyNot yet recruitingNCT06825845
- HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMMRecruitingNCT06822972Phase 2
- Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID ProjectRecruitingNCT06821880
- Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological CancerNot yet recruitingNCT06817759Not applicable
- A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple MyelomaNot yet recruitingNCT06799676Phase 1/2
- A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple MyelomaRecruitingNCT06799026Phase 1
- BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple MyelomaRecruitingNCT06793449Phase 2
- A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple MyelomaRecruitingNCT06791681Early Phase 1
- Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation TreatmentRecruitingNCT06789003Not applicable
- Proteomic Analysis of Patients Undergoing Bariatric SurgeryNot yet recruitingNCT06787807Not applicable
- Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple MyelomaRecruitingNCT06785415Phase 1/2
- Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T TreatmentRecruitingNCT06784167
- A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological TumorsRecruitingNCT06783816Not applicable
- A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingNCT06768489Phase 1
- A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease RecurrenceRecruitingNCT06767254
- Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)RecruitingNCT06759181Phase 1/2
- Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic MalignanciesRecruitingNCT06758713Phase 1
- Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT06758375Phase 2
- Multi-center Screening for Serum M ProteinNot yet recruitingNCT06750965
- SIL as Maintenance Therapy in Multiple MyelomaNot yet recruitingNCT06744894Phase 2
- To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple MyelomaNot yet recruitingNCT06742138Phase 3
- A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple MyelomaRecruitingNCT06732232Early Phase 1
- A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell LeukemiaRecruitingNCT06730256Early Phase 1
- Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma LesionsNot yet recruitingNCT06720207
- a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaRecruitingNCT06718270Early Phase 1
- A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple MyelomaRecruitingNCT06717113Early Phase 1
- Elranatamab in Relapsed/Refractory Multiple MyelomaRecruitingNCT06711705Phase 2
- Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple MyelomaNot yet recruitingNCT06705725Phase 1
- A Clinical Study of TQB2029 for Injection in Subjects With Multiple MyelomaRecruitingNCT06700395Phase 1
- A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in KoreaRecruitingNCT06698887
- Risk Stratification and MRD-driven Maintenance for MM After ASCTRecruitingNCT06697483Not applicable
- Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal GammopathyRecruitingNCT06690593
- Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) PatientsRecruitingNCT06682156
- A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell TransplantRecruitingNCT06679829Phase 2
- A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)RecruitingNCT06679101Phase 3
- A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple MyelomaRecruitingNCT06669247Phase 1/2
- An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients with Relapsed/Refractory Multiple MyelomaRecruitingNCT06668792Phase 2
- 5p15/ 9q22/ 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma PatientsNot yet recruitingNCT06667583
- A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT06659770
- Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple MyelomaRecruitingNCT06659276
- An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaNot yet recruitingNCT06655519Phase 1
- Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06645678Phase 1/2
- CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot StudyRecruitingNCT06644625
- BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple MyelomaRecruitingNCT06644443Phase 1/2
- A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingNCT06644118Phase 1
- Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)RecruitingNCT06630104Not applicable
- Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary DiseaseRecruitingNCT06627751Phase 2
- Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal FunctionRecruitingNCT06623630Phase 1
- SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT06622005Phase 1
- Study of ODX (OsteoDex) in Multiple MyelomaRecruitingNCT06616389Phase 1/2
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)RecruitingNCT06615479Phase 3
- Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple MyelomaNot yet recruitingNCT06594211Not applicable
- Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose MelphalanRecruitingNCT06588413Phase 3
- Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT06581640Phase 2
- Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple MyelomaNot yet recruitingNCT06580223Phase 3
- Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot TrialRecruitingNCT06580002Phase 2
- A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06574568Phase 1
- Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple MyelomaRecruitingNCT06574126Phase 2
- Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without DexamethasoneRecruitingNCT06561854Phase 3
- Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUSRecruitingNCT06559033
- DAratumumab and REvlimid REfractory MMRecruitingNCT06541860
- Intestinal Flora and Immunity in Monoclonal Gammopathy PatientsRecruitingNCT06539832
- ATRA and Carfilzomib in Plasma Cell Myeloma PatientsRecruitingNCT06536413Phase 1/2
- Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma PatientsRecruitingNCT06520176Phase 3
- Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMMRecruitingNCT06518551Phase 1/2
- Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple MyelomaRecruitingNCT06517017Phase 2
- Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MMRecruitingNCT06515262Not applicable
- Integrative Therapies in Multiple MyelomaRecruitingNCT06515249Not applicable
- Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsRecruitingNCT06514508Phase 3
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsRecruitingNCT06508983Phase 3
- Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma PatientsRecruitingNCT06505369Phase 2
- Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMMRecruitingNCT06503107Phase 1/2
- A Study to Evaluate Preventive Treatments for GPRC5D-related Oral EventsRecruitingNCT06500884Phase 2
- A Study of QLS4131 in Patients With Recurrent or Refractory Multiple MyelomaNot yet recruitingNCT06500507Phase 1
- A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple MyelomaRecruitingNCT06497738
- Early Palliative Care for Patients With Multiple Myeloma and Aggressive LymphomaRecruitingNCT06485076Not applicable
- Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT06484829Phase 1/2
- A Clinical Study of SHR-9539 in Patients With Multiple MyelomaRecruitingNCT06484777Phase 1
- Measurable Residual Disease-Guided Post-Transplant Elranatamab MaintenanceRecruitingNCT06483100Phase 2
- Bleeding in Multiple MyelomaNot yet recruitingNCT06482931
- Study on the Clinical Efficacy of Teclistamab and TalquetamabRecruitingNCT06477783
- Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple MyelomaRecruitingNCT06474182Not applicable
- LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT06472479Not applicable
- Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple MyelomaRecruitingNCT06465316Phase 1
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)RecruitingNCT06464991Phase 3
- Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or NotRecruitingNCT06463717
- Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple MyelomaRecruitingNCT06461988Phase 2
- Clinical Outcomes and Prognostic Factors in Multiple Myeloma PatientsNot yet recruitingNCT06457464
- Engineered Dendritic Cell Vaccines for Multiple MyelomaNot yet recruitingNCT06435910Phase 1
- Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06433947Phase 1
- Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or PlasmacytomaNot yet recruitingNCT06429150Phase 1/2
- Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple MyelomaRecruitingNCT06421675Phase 2
- Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.RecruitingNCT06409767Not applicable
- Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingNCT06409702Phase 4
- Study of CT071 Injection in High Risk Newly Diagnosed Multiple MyelomaRecruitingNCT06407947Early Phase 1